JP2011512163A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011512163A5 JP2011512163A5 JP2010547822A JP2010547822A JP2011512163A5 JP 2011512163 A5 JP2011512163 A5 JP 2011512163A5 JP 2010547822 A JP2010547822 A JP 2010547822A JP 2010547822 A JP2010547822 A JP 2010547822A JP 2011512163 A5 JP2011512163 A5 JP 2011512163A5
- Authority
- JP
- Japan
- Prior art keywords
- chromosome
- autism
- cnv
- snp
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000349 chromosome Anatomy 0.000 claims 59
- 238000000034 method Methods 0.000 claims 31
- 206010003805 Autism Diseases 0.000 claims 26
- 208000020706 Autistic disease Diseases 0.000 claims 26
- 102000039446 nucleic acids Human genes 0.000 claims 19
- 108020004707 nucleic acids Proteins 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 19
- 101100495925 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr3 gene Proteins 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 12
- 208000029560 autism spectrum disease Diseases 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 230000007372 neural signaling Effects 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 108700028369 Alleles Proteins 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 102000000905 Cadherin Human genes 0.000 claims 1
- 108050007957 Cadherin Proteins 0.000 claims 1
- 230000021164 cell adhesion Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000004766 neurogenesis Effects 0.000 claims 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3013608P | 2008-02-20 | 2008-02-20 | |
| US61/030,136 | 2008-02-20 | ||
| US10716308P | 2008-10-21 | 2008-10-21 | |
| US61/107,163 | 2008-10-21 | ||
| PCT/US2009/034784 WO2009105718A1 (en) | 2008-02-20 | 2009-02-20 | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011512163A JP2011512163A (ja) | 2011-04-21 |
| JP2011512163A5 true JP2011512163A5 (enExample) | 2012-04-05 |
| JP6078211B2 JP6078211B2 (ja) | 2017-02-15 |
Family
ID=40985948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010547822A Expired - Fee Related JP6078211B2 (ja) | 2008-02-20 | 2009-02-20 | 自閉症および自閉症の表現型に関連する遺伝子変化ならびに自閉症の診断および治療に対するその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9783851B2 (enExample) |
| EP (1) | EP2257644B1 (enExample) |
| JP (1) | JP6078211B2 (enExample) |
| AU (1) | AU2009217278B2 (enExample) |
| CA (1) | CA2716375C (enExample) |
| WO (1) | WO2009105718A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0918868B8 (pt) | 2008-09-18 | 2021-05-25 | Naurex Inc | compostos moduladores do receptor de nmda e composições compreendendo os mesmos |
| WO2010056897A1 (en) * | 2008-11-12 | 2010-05-20 | University Of Utah Research Foundation | Autism associated genetic markers |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| EP2493471B1 (en) | 2009-10-26 | 2019-11-27 | Thomas Julius Borody | Novel enteric combination therapy |
| WO2012027491A1 (en) | 2010-08-24 | 2012-03-01 | The Children's Hospital Of Philadelphia | Association of rare recurrent genetic variations to attention-deficit, hyperactivity disorder (adhd) and methods of use thereof for the diagnosis and treatment of the same |
| SG10202010665YA (en) * | 2011-04-27 | 2020-11-27 | Univ Northwestern | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
| WO2012173809A2 (en) * | 2011-06-02 | 2012-12-20 | Ehli Erik | Method of identifying de novo copy number variants (cnv) using mz twins discordant for attention problems/disorders |
| CA2798906A1 (en) * | 2011-12-22 | 2013-06-22 | Mohammed Uddin | Genome-wide detection of genomic rearrangements and use of genomic rearrangements to diagnose genetic disease |
| US20130210657A1 (en) * | 2012-01-25 | 2013-08-15 | The Hospital For Sick Children | Method of Determining Risk of Autism Spectrum Disorder |
| AU2013230045A1 (en) * | 2012-03-05 | 2014-09-11 | Berg Llc | Compositions and methods for diagnosis and treatment of pervasive developmental disorder |
| AU2013229381A1 (en) * | 2012-03-09 | 2014-09-25 | Integragen | A genotyping test for assessing risk of autism |
| US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| CN104520435A (zh) | 2012-04-02 | 2015-04-15 | 博格有限责任公司 | 基于细胞的探询式分析及其应用 |
| WO2014012144A1 (en) * | 2012-07-20 | 2014-01-23 | The University Of Melbourne | Method of diagnosing or prognosing a neurological disorder |
| TR201908596T4 (tr) | 2013-01-29 | 2019-07-22 | Aptinyx Inc | Spiro-laktam NMDA reseptörü modülatörleri ve bunların kullanımları. |
| KR20150110787A (ko) | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| KR102410989B1 (ko) | 2013-01-29 | 2022-06-17 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| SG11201505862TA (en) | 2013-01-29 | 2015-08-28 | Naurex Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| KR20150110586A (ko) | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| US11219617B2 (en) | 2014-05-30 | 2022-01-11 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating autism |
| WO2016040725A1 (en) | 2014-09-11 | 2016-03-17 | Berg Llc | Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data |
| WO2016057810A1 (en) * | 2014-10-08 | 2016-04-14 | The Broad Institute, Inc. | Markers for assessing risk of developing or having obsessive compulsive disorder |
| WO2016109449A1 (en) * | 2014-12-29 | 2016-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of diagnosing autism spectrum disorders |
| ES2909329T3 (es) | 2015-09-08 | 2022-05-06 | Childrens Hospital Philadelphia | Activador no selectivo del receptor metabotrópico de glutamato para el tratamiento del trastorno de déficit de atención |
| KR102128675B1 (ko) | 2016-05-19 | 2020-06-30 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| AU2017306136B2 (en) | 2016-08-01 | 2021-10-21 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| PE20190501A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores nmda espiro-lactam y metodos de uso de los mismos |
| JP2019527235A (ja) | 2016-08-01 | 2019-09-26 | アプティニックス インコーポレイテッド | スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用 |
| AU2017306152A1 (en) | 2016-08-01 | 2019-01-31 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| PE20190504A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactam y uso de los mismos |
| MX2020008107A (es) | 2018-01-31 | 2020-09-25 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos. |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071314B2 (en) * | 2001-12-14 | 2011-12-06 | President And Fellows Of Harvard College | Immunocellular receptors related to neurological disorders and therapeutic uses thereof |
| US20060194201A1 (en) * | 2002-10-10 | 2006-08-31 | Jean-Pierre Fryns | Autism gene |
-
2009
- 2009-02-20 JP JP2010547822A patent/JP6078211B2/ja not_active Expired - Fee Related
- 2009-02-20 CA CA2716375A patent/CA2716375C/en active Active
- 2009-02-20 US US12/918,508 patent/US9783851B2/en active Active
- 2009-02-20 WO PCT/US2009/034784 patent/WO2009105718A1/en not_active Ceased
- 2009-02-20 AU AU2009217278A patent/AU2009217278B2/en not_active Ceased
- 2009-02-20 EP EP09713119.7A patent/EP2257644B1/en active Active
-
2017
- 2017-10-09 US US15/727,868 patent/US20180148786A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011512163A5 (enExample) | ||
| Liang et al. | Cell-type-specific effects of genetic variation on chromatin accessibility during human neuronal differentiation | |
| Volpi et al. | Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia | |
| JP2010528590A5 (enExample) | ||
| US8187811B2 (en) | Polymorphisms associated with Parkinson's disease | |
| JP2012503985A5 (enExample) | ||
| JP2014533949A5 (enExample) | ||
| CA2881027C (en) | Prognosis biomarkers in cartilage disorders | |
| Ramsey et al. | Cross‐species analysis of the canine and human bladder cancer transcriptome and exome | |
| CN104736723B (zh) | 用于预测对fgf‑18化合物的响应性的遗传标记 | |
| RU2009147281A (ru) | Способы и композиции для диагностики и лечения волчанки | |
| US20190055603A1 (en) | System and method for processing genotype information relating to drug metabolism | |
| JP2013507127A5 (enExample) | ||
| JP2016540729A (ja) | 酢酸グラチラマーへの応答を予測する遺伝子マーカー | |
| RU2012118596A (ru) | Способы лечения, диагностики и мониторинга волчанки | |
| CA3118133A1 (en) | A quantitative algorithm for endometriosis | |
| Quast et al. | Rare variants in TMEM132D in a case–control sample for panic disorder | |
| Fiorentino et al. | Genetic variation in the miR‐708 gene and its binding targets in bipolar disorder | |
| Polakkattil et al. | Methylome-wide and meQTL analysis helps to distinguish treatment response from non-response and pathogenesis markers in schizophrenia | |
| WO2010111080A2 (en) | Optimized treatment of schizophrenia | |
| US20160076104A1 (en) | Methods and compositions for assessment of pulmonary function and disorders | |
| JP2011523552A5 (enExample) | ||
| CA3174572A1 (en) | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters | |
| JP2010525788A (ja) | 心臓血管機能及び障害の評価のための方法及び組成物 | |
| JP5787337B2 (ja) | Ｃ型肝炎の治療効果を予測するためのマーカー群、検査方法及び検査用キット |